These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
329 related items for PubMed ID: 22105817
1. Thymic malignancies: from clinical management to targeted therapies. Kelly RJ, Petrini I, Rajan A, Wang Y, Giaccone G. J Clin Oncol; 2011 Dec 20; 29(36):4820-7. PubMed ID: 22105817 [Abstract] [Full Text] [Related]
5. Do thymic malignancies respond to target therapies? Hu B, Rong H, Han Y, Li Q. Interact Cardiovasc Thorac Surg; 2015 Jun 20; 20(6):855-9. PubMed ID: 25754373 [Abstract] [Full Text] [Related]
7. Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports. Simonelli M, Zucali PA, Suter MB, Lorenzi E, Rubino L, Fatuzzo G, Alloisio M, Santoro A. Future Oncol; 2015 Jun 20; 11(8):1223-32. PubMed ID: 25832879 [Abstract] [Full Text] [Related]
10. Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors. Serpico D, Trama A, Haspinger ER, Agustoni F, Botta L, Berardi R, Palmieri G, Zucali P, Gallucci R, Broggini M, Gatta G, Pastorino U, Pelosi G, de Braud F, Garassino MC. Ann Oncol; 2015 May 20; 26(5):838-847. PubMed ID: 25411417 [Abstract] [Full Text] [Related]
12. Chemotherapeutic and targeted strategies for locally advanced and metastatic esophageal cancer. Forde PM, Kelly RJ. J Thorac Oncol; 2013 Jun 20; 8(6):673-84. PubMed ID: 23591158 [Abstract] [Full Text] [Related]
13. Novel Agents in the Treatment of Thymic Malignancies. Merveilleux du Vignaux C, Maury JM, Girard N. Curr Treat Options Oncol; 2017 Aug 10; 18(9):52. PubMed ID: 28795288 [Abstract] [Full Text] [Related]
14. Treatment updates in advanced thymoma and thymic carcinoma. Gubens MA. Curr Treat Options Oncol; 2012 Dec 10; 13(4):527-34. PubMed ID: 22961051 [Abstract] [Full Text] [Related]
15. Precise Diagnosis and Treatment of Thymic Epithelial Tumors Based on Molecular Biomarkers. Du J, Zhou XJ. Crit Rev Oncog; 2017 Dec 10; 22(5-6):507-514. PubMed ID: 29604928 [Abstract] [Full Text] [Related]
16. Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy. Kossai M, Duchemann B, Boutros C, Caramella C, Hollebecque A, Angevin E, Gazzah A, Bahleda R, Ileana E, Massard C, Vielh P, Soria JC, Besse B. Lung Cancer; 2015 Sep 10; 89(3):306-10. PubMed ID: 26160757 [Abstract] [Full Text] [Related]
17. Targeted therapy for advanced thymic tumors. Rajan A, Giaccone G. J Thorac Oncol; 2010 Oct 10; 5(10 Suppl 4):S361-4. PubMed ID: 20859134 [Abstract] [Full Text] [Related]
19. Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations. Pagano M, Sierra NM, Panebianco M, Rossi G, Gnoni R, Bisagni G, Boni C. Anticancer Res; 2014 Sep 10; 34(9):5105-10. PubMed ID: 25202099 [Abstract] [Full Text] [Related]
20. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Thomas A, Rajan A, Berman A, Tomita Y, Brzezniak C, Lee MJ, Lee S, Ling A, Spittler AJ, Carter CA, Guha U, Wang Y, Szabo E, Meltzer P, Steinberg SM, Trepel JB, Loehrer PJ, Giaccone G. Lancet Oncol; 2015 Feb 10; 16(2):177-86. PubMed ID: 25592632 [Abstract] [Full Text] [Related] Page: [Next] [New Search]